Amylin Symlin dose titration trial
Amylin will submit results of a dose titration study for Symlin in 250 type-1 diabetes patients as an amendment to its NDA in the second-half of 2002. Patients will be followed for six months after a one month period of pramlintide titration; insulin adjustments will be allowed throughout the study, as requested by FDA's Endocrinologic & Metabolic Drugs Advisory Committee July 26 (1"The Pink Sheet" July 30, 2001, p. 5). The dosing data is expected to be included in labeling. Amylin is also conducting short pharmacokinetic and pharmacodynamic trials. Symlin received an "approvable" letter Oct. 12 requesting additional clinical data (2"The Pink Sheet" Oct. 15, 2001, In Brief)...
You may also be interested in...
Amylin hopes that data from two ongoing open-label Symlin trials will address questions outlined by FDA in an "approvable" letter for the diabetes agent
Amylin will conduct additional trials of antidiabetic Symlin (pramlintide) prior to approval. The trials could focus on dose titration. Amylin is discussing clinical protocol for further studies with FDA after the agency deemed the product "approvable" Oct. 12
Amylin is planning a six-week Symlin safety study to evaluate the increased incidence of hypoglycemia associated with the antidiabetic agent, the company said following a July 26 FDA advisory committee recommendation against approval of the drug.